Bausch & Lomb Corp (BLCO) · Oct 28, 2026 · Exec change
Director resignation
Bausch + Lomb’s director resignation is not tied to an operating dispute, but the board will leave the vacancy open and accelerate unvested awards.
Bausch + Lomb is a fully integrated eye-health company spanning contact lenses and consumer products, prescription ophthalmology, and surgical devices, while it continues building growth around its eye-care portfolio. This is a governance change, not an operating reset. Nathalie Bernier is resigning from the board and its Science and Technology Committee effective October 28, 2026. 〔0〕 The filing explicitly says the departure was not caused by disagreement over operations, policies, or practices. 〔1〕
The main change is a smaller board, with no replacement planned for now. That modestly reduces board capacity—particularly on science and technology oversight—but does not change Bausch + Lomb’s strategy, management team, or business execution. 〔2〕
The exit terms add a limited compensation cost, but the filing gives no amount. Bausch + Lomb will pay prorated cash compensation and fully accelerate Bernier’s unvested 2026 restricted share units as part of a mutual release. 〔3〕
Bottom line: This is a narrow, newly disclosed board departure rather than evidence of an operating problem. Leaving the seat open is a small governance negative, largely offset by the filing’s explicit no-disagreement explanation and lack of broader business change.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!